These findings provide rationale for the use of this novel combination approach to treat HPV-negative HNSCC patients and for future combination studies of CXCR1/2 inhibition, docetaxel, and immune-based therapies. The gene discussed is CXCR1; the disease is head and neck squamous cell carcinoma.